Breaking Down Sopra Steria Group SA Financial Health: Key Insights for Investors

Curious how Sopra Steria's latest numbers stack up for investors? With 2024 revenue of €5,776.8 million (organic growth -0.5%) and Q1 2025 revenue of €1,415.0 million (organic contraction -4.9%), the group faces regional pressures-most notably a -7.7% organic decline in the UK for H1 2025-while guiding 2025 organic revenue between -2.5% and +0.5%; profitability shows resilience with operating profit on business activity of €564.7 million in 2024 (operating margin 9.8%, +0.4pp) and RoCE before tax at 21.5% in 2024, net profit attributable to the Group rising 15.3% to €142.0 million in H1 2025 and EPS up 19.2% to €7.29; balance-sheet strength is underlined by net financial debt of €696.8 million (1.17x pro forma 12m rolling EBITDA as of June 2025), a debt-to-equity ratio improved to 19.3% in 2024, completion of a €150 million share buyback in January 2025 (reducing shares by 4.2%), and free cash flow of €432.1 million in 2024 despite a negative H1 2025 FCF of €145.9 million due to seasonal receivables-valuation metrics show a market cap around €3.5 billion, analysts forecasting ~7.2% annual earnings growth and 2.4% revenue CAGR, a proposed 2024 dividend of €4.65 per share, and medium-term targets of 2-5% organic growth and a 10-11% operating margin alongside growth levers in defense, cybersecurity and AI, counterbalanced by risks like delayed receivables, rising social contributions and challenging UK market conditions-read on for the detailed breakdown.

Sopra Steria Group SA (SOP.PA) - Revenue Analysis

• Full-year 2024 revenue: €5,776.8 million (‑0.5% vs 2023)
• Organic growth 2024: ‑0.5%
• Q1 2025 revenue: €1,415.0 million; organic contraction: ‑4.9% (slightly better than the expected ‑5% to ‑6%)
• UK & Europe: notable declines; UK organic contraction in H1 2025: ‑7.7%
• 2025 guidance: organic revenue growth between ‑2.5% and +0.5%

• Market context: fourth-quarter 2024 weakness drove much of the annual decline, reflecting client spend caution across public and commercial segments.
• Geographic mix: UK and several European markets underperformed, with the UK particularly impacted in H1 2025.
• Short-term outlook: Q1 2025 showed a smaller-than-expected organic contraction (‑4.9% vs. expected ‑5% to ‑6%), indicating some resilience in new contract wins and delivery continuity.
• Management stance: guidance for 2025 is conservative (‑2.5% to +0.5% organic), signalling a cautious recovery expectation rather than aggressive expansion.

• Quarterly organic growth trajectories vs guidance
• Regional trends in the UK and continental Europe
• Order intake and backlog trends (new bookings and contract renewals)
• Margin stability as a function of revenue mix and cost control

Sopra Steria Group SA (SOP.PA) - Profitability Metrics

Sopra Steria's recent results show improving profitability across several key measures, driven by operating performance and efficient capital use. The following highlights and comparative data focus on operating margins, net profitability and returns on capital for full-year 2024 and the first half of 2025.

• Operating profit on business activity (2024): €564.7 million; operating margin 9.8% (up 0.4 pts vs 2023).
• H1 2025 operating margin on business activity: 9.2% (H1 2024: 9.7%).
• Net profit attributable to the Group (H1 2025): €142.0 million, +15.3% vs H1 2024.
• Net profit margin (H1 2025): 5.0% (H1 2024: 4.2%).
• Return on capital employed (RoCE) before tax: 21.5% in 2024 (2023: 16.5%).
• UK segment operating margin (2024): 12.1%, +1.1 pts vs prior year.

For deeper context on shareholder composition and investor interest that complements these profitability metrics, see Exploring Sopra Steria Group SA Investor Profile: Who's Buying and Why?

Sopra Steria Group SA (SOP.PA) - Debt vs. Equity Structure

• Net financial debt (June 2025): €696.8 million - equals 1.17x pro forma 12‑month rolling EBITDA (before IFRS 16).
• Net financial debt (2024): €382.2 million - a 59.6% decrease vs. prior period.
• Debt-to-equity ratio (end 2024): 19.3% (improved from 47.8% in 2023), indicating materially reduced leverage.
• Share buyback (completed Jan 2025): €150 million, reducing outstanding shares by 4.2%.
• Financial covenant: maximum debt/EBITDA = 3.0x; current reported leverage (~1.17x) is well below covenant.

• Capital structure trend: sharp deleveraging in 2024 reduced financial risk and improved headroom under covenants.
• Liquidity and shareholder returns: the €150m buyback (Jan 2025) signals confidence in cash generation and returns discipline.
• Covenant buffer: with reported leverage near 1.17x, Sopra Steria retains significant margin versus the 3x covenant.

Sopra Steria Group SA (SOP.PA) Liquidity and Solvency

• Free cash flow (2024): €432.1 million, above guidance (~€350 million).
• Free cash flow (H1 2025): -€145.9 million, affected by seasonality and delayed receivables.
• Medium-term free cash flow target: 5%-7% of revenue.
• Net financial debt / EBITDA: 1.17x (H1 2025) vs 1.63x (H1 2024).
• Financial covenant: maximum debt-to-EBITDA 3.0x (current levels well below).
• Capital return: €150 million share buyback completed January 2025.

• Implications for investors:
  • Strong 2024 FCF supports dividend/ buyback capacity and deleveraging.
  • Negative H1 2025 FCF signals working-capital timing risk; monitor receivables and seasonality.
  • Leverage at 1.17x provides headroom vs 3.0x covenant, lowering refinancing risk.

Sopra Steria Group SA (SOP.PA) - Valuation Analysis

The following valuation-focused snapshot highlights the key metrics investors should weigh when assessing Sopra Steria Group SA (SOP.PA).

• Market capitalization: approximately €3.5 billion, placing Sopra Steria among the mid-cap European IT services names.
• H1 2025 EPS: €7.29, up 19.2% year-on-year, signaling improved underlying profitability.
• Analyst consensus growth: earnings +7.2% p.a. and revenue +2.4% p.a. over the forecast horizon.
• Return on equity (projected in 3 years): 14.3%, implying efficient use of shareholder capital if targets are met.
• Shareholder returns and capital actions: completed a €150 million share buyback in January 2025, reducing outstanding shares by 4.2%.
• Dividend policy: proposed dividend for 2024 of €4.65 per share, reflecting a continued cash-return orientation.

Key valuation considerations for investors:

• EPS acceleration in H1 2025 supports valuation rerating potential if growth sustains.
• Moderate revenue growth forecast (2.4% p.a.) suggests margin expansion or buyback-driven EPS uplift will be important to justify multiples.
• The €150m buyback and 4.2% share reduction are accretive to EPS and increase cash return per remaining share; combined with a €4.65 dividend this underscores shareholder-friendly capital allocation.
• Projected ROE of 14.3% is attractive for a services company and is a useful gauge of return generation versus cost of equity.
• Relative valuation should be evaluated against European IT services peers on P/E, EV/EBITDA and ROE; reconcile analyst growth assumptions when comparing multiples.

For context on corporate background and how Sopra Steria operates, see: Sopra Steria Group SA: History, Ownership, Mission, How It Works & Makes Money

Sopra Steria Group SA (SOP.PA) - Risk Factors

The following risk factors highlight the principal near-term and structural challenges facing Sopra Steria Group SA (SOP.PA), with emphasis on operational markets, cash flow dynamics, margin pressure and strategic execution in AI.

• UK market deterioration: organic revenue in the UK contracted by 7.7% in H1 2025, reflecting weak demand and contract timing shifts.
• Working capital & seasonality pressure: delayed receivables collection combined with seasonal effects materially impacted free cash flow in H1 2025.
• Margin headwinds from labor costs: higher social security contributions in France and the UK have eroded operating margins.
• Cautious top‑line outlook: management anticipates organic revenue growth in 2025 of between -2.5% and +0.5%, indicating limited visibility and conservative expectations.
• Recent revenue decline origin: the drop in revenue is linked primarily to challenging market conditions, notably in Q4 2024.
• Strategic AI exposure: the Group is actively developing AI capabilities, entering strategic partnerships and tailoring AI solutions to customer needs-this creates both upside (new services/revenues) and execution/technology risk.

• Operational risk considerations:
  • Concentration of slowdown in the UK could signal regional demand contagion across Europe.
  • Receivables collection delays raise liquidity risk and could force short‑term financing or covenant pressure if prolonged.
  • Labor cost inflation via social security increases compresses margin unless offset by pricing or productivity gains.
• Strategic & execution risks:
  • AI investments require sustained R&D and go‑to‑market execution; partnerships bring integration and IP risks.
  • Guidance range near zero growth implies limited room for error-any further downturn could trigger negative revisions and market reaction.

For context on the Group's positioning and stated priorities, see: Mission Statement, Vision, & Core Values (2026) of Sopra Steria Group SA.

Sopra Steria Group SA (SOP.PA) Growth Opportunities

• Medium-term financial targets: organic revenue growth of 2%-5% annually (2026-2028) and an operating margin on business activity of 10%-11%.
• Capital returns: completion of a €150 million share buyback in January 2025, reducing outstanding shares by 4.2% and enhancing EPS accretion potential.
• M&A and capability expansion: proposed acquisition of Aurexia to bolster management consulting expertise in financial services and expand advisory capacity.

• Defense & cybersecurity positioning: with over 4,000 experts and collaborations with major industrial players, Sopra Steria can capture government and critical-infrastructure spending - a relatively resilient and high-barrier segment.
• AI adoption and services: active involvement in AI development and adaptation of AI to customer needs positions the firm to monetize automation, analytics and next‑gen software projects across existing client bases.
• Consulting uplift via Aurexia: the Aurexia deal is expected to enhance advisory depth in financial services, improving cross‑sell opportunities and higher‑margin consulting revenue.
• Shareholder-friendly moves: the €150M buyback materially cut share count (-4.2%), supporting per‑share metrics and signaling confidence from management on capital allocation.

• Execution levers for hitting targets:
  • Cross-selling digital, cloud and cybersecurity services into public and enterprise accounts.
  • Scaling AI-driven offerings with partner ecosystems and targeted IP development.
  • Integrating Aurexia to accelerate consulting revenue growth and margin mix.